Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist, known for his expertise in spectroscopy and materials research, will provide scientific guidance to support the company's ongoing research initiatives.
Uwe Perbandt, CEO of Viromed Medical AG, expressed enthusiasm about the new appointment, stating, "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
Prof. Rubhausen currently heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg, where he also serves as Managing Director. He is affiliated with the Center for Free-Electron Laser Science (CFEL). His research primarily focuses on advanced spectroscopic methods, including Raman spectroscopy and ellipsometry. He applies these techniques to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH.
With over 180 publications and approximately 4,000 citations, Prof. Rubhausen has contributed to renowned scientific journals, including Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Another focus of his work is the development of AI-supported analysis workflows for complex, high-dimensional datasets, which could prove valuable in analyzing the effects of cold plasma on various materials.
This appointment comes as Viromed Medical AG continues to expand its focus on cold plasma technology for medical applications. The company, listed on the stock exchange since October 2022, operates through its wholly owned subsidiary Viromed Medical GmbH. Cold plasma technology has shown promise in wound healing, disinfection, and other therapeutic areas. By adding Prof. Rubhausen to its advisory board, Viromed aims to deepen its understanding of the interactions between plasma and biological tissues, potentially leading to more effective and safer medical devices.
The implications of this move are significant for the medical technology sector. Cold plasma is a relatively new field in medicine, and rigorous scientific evaluation is crucial for its acceptance and integration into clinical practice. Prof. Rubhausen's expertise in spectroscopy could enable precise characterization of plasma-treated surfaces and tissues, thereby informing the design of better treatment protocols. His background in AI-driven data analysis may also facilitate the interpretation of complex spectroscopic data, accelerating research progress.
For more information about Viromed Medical AG and its technologies, visit their website at viromed-medical-ag.de.
